Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.American Biotech Labs, a developer of a class of products based on the company's patented nano-catalytic SilverSol Technology, has received formal approval from the FDA to market its ASAP wound dressing gel throughout the US.
Subscribe to our email newsletter
The FDA approval letter confirms that American Biotech Labs (ABL) may market ASAP wound dressing gel for the topical management of minor cuts, lacerations, abrasions, first and second degree burns, and skin irritations.
The product utilizes ABL’s SilverSol Technology, which has garnered multiple patents in the US and several countries throughout the world, including a broad-use patent that provides the company with exclusive rights to use its silver-based products to combat many of the destructive pathogens, including malaria, tuberculosis, MRSA and HIV, said ABL.
William Moeller, managing director at American Biotech Labs, said: “We are delighted with the FDA’s decision to grant approval for ABL to broadly market our ASAP wound dressing gel. We feel this is a singularly effective wound care product, and it is a tremendous validation for us that ABL products have now received approval from the FDA as well as from the EPA.”